Clinical Trials and Progress in Metastatic Colon Cancer

Kabir Mody; Tanios Bekaii-Saab

doi:10.1016/j.soc.2017.11.008

Clinical Trials and Progress in Metastatic Colon Cancer

Kabir Mody, Tanios Bekaii-Saab

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide but associated mortality has declined in recent decades. Genomic profiling of the disease has resulted in the definition of subsets of patients—for example, KRAS, NRAS, or BRAF mutated; Her2 amplified; and mismatch repair deficient—which has enabled personalization of therapeutic decision making. These subsets are guiding drug development and combination therapy approaches using both targeted therapies and immunotherapies. Further refinement based on molecular discoveries and the emergence of newer technologies to enable new discoveries allow for great optimism for the future on behalf of patients with colon cancer.

Original language	English (US)
Pages (from-to)	349-365
Number of pages	17
Journal	Surgical Oncology Clinics of North America
Volume	27
Issue number	2
DOIs	https://doi.org/10.1016/j.soc.2017.11.008
State	Published - Apr 2018

Keywords

BRAF
Clinical trials
Colorectal cancer
Her2
Immunotherapy
KRAS

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/j.soc.2017.11.008

Cite this

@article{353e45b0b8cd4b4cb4769a5bff4211de,

title = "Clinical Trials and Progress in Metastatic Colon Cancer",

abstract = "Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide but associated mortality has declined in recent decades. Genomic profiling of the disease has resulted in the definition of subsets of patients—for example, KRAS, NRAS, or BRAF mutated; Her2 amplified; and mismatch repair deficient—which has enabled personalization of therapeutic decision making. These subsets are guiding drug development and combination therapy approaches using both targeted therapies and immunotherapies. Further refinement based on molecular discoveries and the emergence of newer technologies to enable new discoveries allow for great optimism for the future on behalf of patients with colon cancer.",

keywords = "BRAF, Clinical trials, Colorectal cancer, Her2, Immunotherapy, KRAS",

author = "Kabir Mody and Tanios Bekaii-Saab",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2018",

month = apr,

doi = "10.1016/j.soc.2017.11.008",

language = "English (US)",

volume = "27",

pages = "349--365",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Clinical Trials and Progress in Metastatic Colon Cancer

AU - Mody, Kabir

AU - Bekaii-Saab, Tanios

PY - 2018/4

Y1 - 2018/4

N2 - Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide but associated mortality has declined in recent decades. Genomic profiling of the disease has resulted in the definition of subsets of patients—for example, KRAS, NRAS, or BRAF mutated; Her2 amplified; and mismatch repair deficient—which has enabled personalization of therapeutic decision making. These subsets are guiding drug development and combination therapy approaches using both targeted therapies and immunotherapies. Further refinement based on molecular discoveries and the emergence of newer technologies to enable new discoveries allow for great optimism for the future on behalf of patients with colon cancer.

AB - Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide but associated mortality has declined in recent decades. Genomic profiling of the disease has resulted in the definition of subsets of patients—for example, KRAS, NRAS, or BRAF mutated; Her2 amplified; and mismatch repair deficient—which has enabled personalization of therapeutic decision making. These subsets are guiding drug development and combination therapy approaches using both targeted therapies and immunotherapies. Further refinement based on molecular discoveries and the emergence of newer technologies to enable new discoveries allow for great optimism for the future on behalf of patients with colon cancer.

KW - BRAF

KW - Clinical trials

KW - Colorectal cancer

KW - Her2

KW - Immunotherapy

KW - KRAS

UR - http://www.scopus.com/inward/record.url?scp=85042790466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042790466&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2017.11.008

DO - 10.1016/j.soc.2017.11.008

M3 - Review article

C2 - 29496094

AN - SCOPUS:85042790466

SN - 1055-3207

VL - 27

SP - 349

EP - 365

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 2

ER -

Clinical Trials and Progress in Metastatic Colon Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this